WO2008035735A1 - Procédé de production d'un composé de succinimide optiquement actif - Google Patents
Procédé de production d'un composé de succinimide optiquement actif Download PDFInfo
- Publication number
- WO2008035735A1 WO2008035735A1 PCT/JP2007/068267 JP2007068267W WO2008035735A1 WO 2008035735 A1 WO2008035735 A1 WO 2008035735A1 JP 2007068267 W JP2007068267 W JP 2007068267W WO 2008035735 A1 WO2008035735 A1 WO 2008035735A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- optically active
- substituted
- production method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
Definitions
- the present invention relates to a novel process for producing an optically active succinimide compound, which is excellent in operability, can be carried out at a low cost, and has high optical selectivity. It is a useful compound that is used as an intermediate material for pharmaceuticals.
- a method for producing an optically active succinimide compound has been eagerly desired and has been actively studied.
- a versatile production method there is known a method in which a racemic compound and diastereomeric salt of a succinimide compound are produced using an optically active amine (such as cinchonidine) and then separated by recrystallization (Patent Document 1, Patent).
- Patent Document 1 a method in which a racemic compound and diastereomeric salt of a succinimide compound are produced using an optically active amine (such as cinchonidine) and then separated by recrystallization
- Patent Document 1 See Literature 2, Patent Literature 3, and Patent Literature 4.
- several methods for stereoselectively hydrolyzing racemic compounds are known (see, for example, Non-Patent Document 1, Non-Patent Document 2, and Non-Patent Document 3).
- Patent Document 1 JP-A-6-192222
- Patent Document 2 JP 2002-37771
- Patent Document 3 Japanese Patent Laid-Open No. 2002-47267
- Patent Document 4 Japanese Patent Application Laid-Open No. 2002-47268
- Non-Patent Document 1 Tetrahedron-Letters vol.28, No40, 4661 -4664 (1987).
- Non-Patent Document 2 Tetrahedron-Letters vol.27, No22, 2543-2546 (1986).
- Non-Patent Document 3 Journal 'Ob' Organic 'Chemistry, vol.53, ⁇ .8, 1607— 1611 (1988).
- Non-Patent Document 4 Journal 'Ob' Medicinal 'Chemistry, vol.41, No.21, 4118-412 9 (1998).
- Cinchonidine is very expensive, and it is difficult to supply a large quantity with a small amount of distribution.
- the present inventors have found that the above problems can be solved by using an enzymatic hydrolysis reaction, and have completed the present invention. That is, the present invention
- R 1 is an alkyl group having 1 to 12 carbon atoms which may be linear, branched or cyclic, or substituted, may be, 6 carbon atoms! /, And 12 Represents an aromatic group
- R 2 and R 3 may be each independently a hydrogen atom, straight chain, branched or cyclic! /, 1 carbon atom! /, 12 alkyl group, or may be substituted! / , A 2 or 6 carbon acyl group, substituted! /, Or even! /, A 1 carbon atom or 6 alkoxycarbonyl group, an aromatic ring substituted , May! /, Substituted benzinore group or aromatic ring! /, May! /, Force representing benzyloxycarbonyl group, or
- R 2 and R 3 can be joined together with the nitrogen atom to form a ring
- R 4 may be a hydrogen atom, a linear, branched or cyclic alkyl group having 1 to 12 carbon atoms or substituted! /, May! /, 6 carbon atoms! /
- And 12 Represents an aromatic group.
- the racemic compound of the succinimide compound represented by formula (2) is treated in the presence of a hydrolase, one of the enantiomers is selectively hydrolyzed, and then subjected to post-treatment.
- the hydrolase is a lipase originating from Penicillium, a lipase originating from Candida antarctica, or an esterase derived from pig liver (PLE).
- PLE pig liver
- optically active succinimide compound represented by the formula (2) is represented by the formula (3):
- optically active succinimide compound represented by the formula (2) is represented by the formula (4):
- R 1 represents a linear or branched alkyl group having 1 to 6 carbon atoms
- R 2 represents a benzyloxycarbonyl group in which the aromatic ring part may be substituted
- [4] is a compound in which R 4 represents a hydrogen atom
- step (b) a step of converting the benzyloxycarbonylamino group of the optically active succinimide compound produced in the step (a) into an amino group;
- step (d) converting the pyrrole-1-yl group of the product obtained in step (c) to a 2-trichloroacetylpyrrole-1-yl group;
- step (e) A step of reacting the product obtained in the step (d) with 4-bromo-2-fluorobenzylamine to convert it into a compound A. Manufacturing method.
- an optically active succinimide compound useful as an intermediate raw material for pharmaceuticals and the like can be produced inexpensively and simply.
- an alkyl group having 1 to 12 carbon atoms which may be linear, branched or cyclic is a linear, branched or cyclic carbon group having 1 to 12 carbon atoms.
- the aromatic group having 6 to 12 carbon atoms that may be substituted includes a halogen atom, an alkyl group having 1 to 12 carbon atoms, a cyan group, a nitro group, an alkylcarbonyl group having 1 to 12 carbon atoms, carbon It is substituted with one or more substituents selected from the same or different substituents selected from alkyloxy groups having 1 to 12 atoms, di (alkyl having 1 or 12 carbon atoms) amino groups, etc. , A phenyl group, a naphthyl group, and the like.
- Examples of the optionally substituted acyl group having 2 to 6 carbon atoms include one or more substituents selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a nitro group, and a cyano group. Substituted! /, May!
- the C1-C6 alkoxycarbonyl group which may be substituted is one or more substituents which are the same or different and are selected from a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a nitro group, a cyano group and the like.
- the aromatic ring portion may be substituted! /
- the benzyl group has an aromatic portion as a halogen atom, an alkyl group having 1 to 12 carbon atoms, a cyan group, a nitro group, or 1 to 12 carbon atoms. Substituted with one or more different substituents selected from alkylcarbonyl groups, alkyloxy groups having 1 to 12 carbon atoms, di (alkyl having 1 to 12 carbon atoms) amino groups, etc.
- the aromatic ring moiety may be substituted! /
- the benzyloxycarbonyl group includes a halogen atom, an alkyl group having 1 to 12 carbon atoms, a cyan group, a nitro group, and a carbon atom number. 1 or 12 alkylcarbonyl group, 1 to 12 alkyloxy group, di (C1 to C12 alkyl) amino group, etc. Represents an optionally substituted benzyloxycarbonyl group.
- R 2 and R 3 are combined to form a ring, R 2 and R 3 are joined together, and together with N, a piperidine ring, a pyrrolidine ring, a succinimide ring And a case of forming a maleimide ring and the like.
- R 1 examples include methyl group, ethyl group, n-propyl group, i-propyl group, n butyl group, i butyl group, s butyl group, t butyl group, benzyl group and the like.
- R 2 examples include a hydrogen atom, a methyl group, an ethyl group, and an n propyl group.
- R 3 includes benzyl, benzyloxycarbonyl, acetyl, and t-butyloxy. Examples include a sicarbonyl group.
- R 4 examples include a hydrogen atom, methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, s-butyl group, t-butyl group, benzyl group and the like.
- R 4 examples include a hydrogen atom, methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, s-butyl group, t-butyl group, benzyl group and the like.
- hydrolases examples include proteases, esterases, lipases, etc., but preferably lipases originating from penicillium (eg Lipase R; manufactured by Amano Enzyme), Candida antarctica (Candida ant arctica) origin lipase (for example, Chirazyme L-2 (Rosshu), pig liver-derived esterase (PLE); for example, Sigma, Roche, Biocatalyst Esterase (PLE) extracted from pig liver is more preferable.
- penicillium eg Lipase R; manufactured by Amano Enzyme
- Candida antarctica Candida ant arctica origin lipase
- PLE pig liver-derived esterase
- Sigma Roche
- Biocatalyst Esterase (PLE) extracted from pig liver is more preferable.
- the hydrolase may be a natural type or a commercially available product such as an immobilization product, and may be used alone or in combination of two or more.
- the amount of hydrolase used can usually be in the range of 0.01 to 3000 mg, preferably 0.1 to 1 OO mg, based on the succinimide compound lg represented by the formula (1). It is a range.
- the solvent water, a buffer solvent, an organic solvent, a mixed solvent of an organic solvent and water, or a mixed solvent of an organic solvent and a buffer solvent is used.
- an acid compound and an alkaline compound are mixed in water and adjusted to an arbitrary pH.
- the acidic compound used in the buffer include phosphoric acid, citrate, boric acid, acetic acid and the like, and phosphoric acid and citrate are preferably used.
- alkaline compound examples include powers such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and ammonia, preferably sodium hydroxide and potassium hydroxide.
- the pH of the buffer can be used in the range of pH 3.0 to 10.0, and preferably in the range of pH 4.0 to 8.0.
- the buffer concentration can be used in the range of 0.01 to 2. Omol / L, preferably in the range of 0.03 to 0.3 mol / L.
- organic solvent examples include alcohols that are stable under the reaction conditions and do not interfere with the intended reaction, and are not particularly limited as long as they are used (for example, ethanol, propanol, butanol, octanol, etc.), cellosolve.
- aprotic polar organic solvents for example, dimethylformamide, dimethylsulfoxide, dimethylacetamide, tetramethylurea, sulfolane, N-methylpyrrolidone, N, N-dimethylenomidazo Lysinone, etc.
- etherenoles eg, jetinoleethenole, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, etc.
- aliphatic hydrocarbons eg, pentane, hexane, c-hexane, octane, decane, Decalin, petroleum ether ), Aromatic hydrocarbons (benzene, black benzene, o dichlorobenzene, nitrobenzene, tolylene, xylene, mesitylene, tetralin, etc.), hal
- the said organic solvent can be used individually by 1 type or in mixture of 2 or more types.
- the amount of the solvent used is usually 1 to 200 times by mass, preferably 5 to 50 times by mass with respect to the succinimide compound represented by the formula (1).
- the reaction temperature can usually be from o ° c to the boiling point of the solvent to be used, but it is preferably 0 to 80 ° C, more preferably 20 to 50 ° C.
- an acidic compound or an alkaline compound can be added dropwise, for example, as an aqueous solution in response to a change in pH during the reaction, and adjusted to an arbitrary pH.
- the target optically active succinimide compound represented by the formula (2) is obtained by, for example, filtering the reaction solution to remove insolubles after the completion of the reaction, extracting the reaction product with an appropriate solvent, and washing with water. Can be obtained by removing the hydrolyzate and concentrating the solvent under reduced pressure. If necessary, it can be purified by recrystallization, distillation, silica gel column chromatography or the like.
- the compound represented by formula (1) is treated with a microorganism capable of producing a hydrolase, for example, a culture such as Penicillium or Candida antarctica, or a treated product thereof. Therefore, the force S can be used to produce the compound represented by the formula (2).
- a microorganism capable of producing a hydrolase for example, a culture such as Penicillium or Candida antarctica, or a treated product thereof. Therefore, the force S can be used to produce the compound represented by the formula (2).
- R 1 is an alkyl group having 1 or 6 carbon atoms which may be linear or branched, and R 2 is substituted with an aromatic ring! /
- the optically active succinimide compound represented by the above formula (3), which is a benzyloxycarbonyl group and R 3 and R 4 are hydrogen atoms, is useful as an intermediate of compound A that is promising as a pharmaceutical product. It explains the manufacturing method related to this.
- step (ii) reacting the amino group of the product obtained in step (i) with 2,5-dimethoxytetrahydrofuran in acetic acid;
- step (iii) reacting the product obtained in step (ii) with trichloroacetyl chloride in black mouth form; (iv) reacting the product obtained in step (iii) with a mixture of triethylamine and 4-bromo-2-fluorobenzylamine hydrochloride in dry dimethylformamide; (V) obtained by step (iv).
- the obtained compound A is crystallized and isolated from a mixed solvent of ethyl acetate and hexane,
- optical purity of the optically active succinimide compound represented by the formula (2) was determined from the area ratio with the enantiomer from the measurement result by high performance liquid chromatography using the optically active column.
- the quantitative yield of the optically active succinimide compound represented by the formula (2) was determined by performing quantitative analysis using diaryl phthalate as an internal standard substance using reversed-phase high performance liquid chromatography. .
- the 2-benzyloxycarbonylamino-2-ethoxycarbonyl succinimide used in this example was synthesized by the method described in JP-A-5-186472.
- this reaction solution contained 2.4 g (quantitative yield 48.6%) of (R) -2 benzyloxycarbonylamino-2-ethoxycarboxylconuccinimide having an optical purity of 97.5% ee. It was.
- the method of the present invention provides a novel method for producing an optically active succinimide compound useful as an intermediate raw material for pharmaceuticals and the like.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07807631A EP2071033A4 (en) | 2006-09-20 | 2007-09-20 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE COMPOUND |
JP2008535383A JP5149802B2 (ja) | 2006-09-20 | 2007-09-20 | 光学活性コハク酸イミド化合物の製造法 |
US12/311,048 US7994342B2 (en) | 2006-09-20 | 2007-09-20 | Method for producing optically active succinimide compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006254446 | 2006-09-20 | ||
JP2006-254446 | 2006-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008035735A1 true WO2008035735A1 (fr) | 2008-03-27 |
Family
ID=39200559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/068267 WO2008035735A1 (fr) | 2006-09-20 | 2007-09-20 | Procédé de production d'un composé de succinimide optiquement actif |
Country Status (6)
Country | Link |
---|---|
US (1) | US7994342B2 (ja) |
EP (1) | EP2071033A4 (ja) |
JP (1) | JP5149802B2 (ja) |
KR (1) | KR20090057387A (ja) |
CN (1) | CN101517092A (ja) |
WO (1) | WO2008035735A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010090031A1 (ja) | 2009-02-06 | 2010-08-12 | 大日本住友製薬株式会社 | 光学活性スクシンイミド誘導体の製造方法及びその中間体 |
WO2012014953A1 (ja) * | 2010-07-29 | 2012-02-02 | 大日本住友製薬株式会社 | 光学活性スクシンイミド誘導体の製造方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04283562A (ja) * | 1991-03-13 | 1992-10-08 | Sumitomo Chem Co Ltd | イミド誘導体およびその製造法 |
JPH05186472A (ja) | 1991-06-26 | 1993-07-27 | Dainippon Pharmaceut Co Ltd | テトラヒドロピロロ〔1,2−a〕ピラジン−4−スピロ−3′−ピロリジン誘導体及びそれを有効成分とする糖尿病性合併症治療薬 |
JPH06192222A (ja) | 1992-12-25 | 1994-07-12 | Dainippon Pharmaceut Co Ltd | コハク酸イミド誘導体 |
JP2002037771A (ja) | 2000-07-25 | 2002-02-06 | Nippon Kasei Chem Co Ltd | 光学活性ジオキソピロリジン誘導体の光学分割方法 |
JP2002047267A (ja) | 2000-07-27 | 2002-02-12 | Nippon Kasei Chem Co Ltd | 光学活性ジオキソピロリジン誘導体の製造方法 |
JP2002047268A (ja) | 2000-07-27 | 2002-02-12 | Nippon Kasei Chem Co Ltd | 光学活性ジオキソピロリジン誘導体の製造方法 |
-
2007
- 2007-09-20 EP EP07807631A patent/EP2071033A4/en not_active Withdrawn
- 2007-09-20 CN CNA2007800345768A patent/CN101517092A/zh active Pending
- 2007-09-20 JP JP2008535383A patent/JP5149802B2/ja not_active Expired - Fee Related
- 2007-09-20 WO PCT/JP2007/068267 patent/WO2008035735A1/ja active Application Filing
- 2007-09-20 US US12/311,048 patent/US7994342B2/en not_active Expired - Fee Related
- 2007-09-20 KR KR1020097005321A patent/KR20090057387A/ko not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04283562A (ja) * | 1991-03-13 | 1992-10-08 | Sumitomo Chem Co Ltd | イミド誘導体およびその製造法 |
JPH05186472A (ja) | 1991-06-26 | 1993-07-27 | Dainippon Pharmaceut Co Ltd | テトラヒドロピロロ〔1,2−a〕ピラジン−4−スピロ−3′−ピロリジン誘導体及びそれを有効成分とする糖尿病性合併症治療薬 |
JPH06192222A (ja) | 1992-12-25 | 1994-07-12 | Dainippon Pharmaceut Co Ltd | コハク酸イミド誘導体 |
JP2002037771A (ja) | 2000-07-25 | 2002-02-06 | Nippon Kasei Chem Co Ltd | 光学活性ジオキソピロリジン誘導体の光学分割方法 |
JP2002047267A (ja) | 2000-07-27 | 2002-02-12 | Nippon Kasei Chem Co Ltd | 光学活性ジオキソピロリジン誘導体の製造方法 |
JP2002047268A (ja) | 2000-07-27 | 2002-02-12 | Nippon Kasei Chem Co Ltd | 光学活性ジオキソピロリジン誘導体の製造方法 |
Non-Patent Citations (5)
Title |
---|
JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 21, 1998, pages 4118 - 4129 |
JOURNAL OF ORGANIC CHEMISTRY, vol. 53, no. 8, 1988, pages 1607 - 1611 |
See also references of EP2071033A4 |
TETRAHEDRON LETTERS, vol. 27, no. 22, 1986, pages 2543 - 2546 |
TETRAHEDRON LETTERS, vol. 28, no. 40, 1987, pages 4661 - 4664 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010090031A1 (ja) | 2009-02-06 | 2010-08-12 | 大日本住友製薬株式会社 | 光学活性スクシンイミド誘導体の製造方法及びその中間体 |
US8633001B2 (en) | 2009-02-06 | 2014-01-21 | Dainippon Sumitomo Pharma Co., Ltd. | Process for producing optically active succinimide derivatives and intermediates thereof |
JP5697998B2 (ja) * | 2009-02-06 | 2015-04-08 | 大日本住友製薬株式会社 | 光学活性スクシンイミド誘導体の製造方法及びその中間体 |
US9434737B2 (en) | 2009-02-06 | 2016-09-06 | Sumitomo Dainippon Pharma Co., Ltd. | Process for producing optically active succinimide derivatives and intermediates thereof |
WO2012014953A1 (ja) * | 2010-07-29 | 2012-02-02 | 大日本住友製薬株式会社 | 光学活性スクシンイミド誘導体の製造方法 |
US8900830B2 (en) | 2010-07-29 | 2014-12-02 | Sumitomo Dainippon Pharma Co., Ltd. | Process for producing optically active succinimide derivatives |
JP5844257B2 (ja) * | 2010-07-29 | 2016-01-13 | 大日本住友製薬株式会社 | 光学活性スクシンイミド誘導体の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US7994342B2 (en) | 2011-08-09 |
JP5149802B2 (ja) | 2013-02-20 |
KR20090057387A (ko) | 2009-06-05 |
EP2071033A4 (en) | 2010-05-26 |
EP2071033A1 (en) | 2009-06-17 |
JPWO2008035735A1 (ja) | 2010-01-28 |
CN101517092A (zh) | 2009-08-26 |
US20100003729A1 (en) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3789938B2 (ja) | 酵素触媒作用アシル化による1級及び2級のヘテロ原子置換アミンのラセミ体分割 | |
JP5096435B2 (ja) | 光学活性α−メチルシステイン誘導体の製造方法 | |
WO2019232706A1 (zh) | 一种制备普瑞巴林中间体(r)-3-(氨甲酰甲基)-5-甲基己酸的方法 | |
US20240150344A1 (en) | Process for producing acyloxymethyl esters of (4s)-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylic acid | |
Liljeblad et al. | Enzymatic methods for the preparation of enantiopure malic and aspartic acid derivatives in organic solvents | |
WO2008035735A1 (fr) | Procédé de production d'un composé de succinimide optiquement actif | |
WO2004003001A1 (en) | Process for the enzymatic resolution of 1,3-dioxolane-4-carboxylates | |
US20050153401A1 (en) | Process for preparing optically active beta-aminocarboxylic acids from racemic n-acylated beta-aminocarboxylic acids | |
ES2349484T3 (es) | Síntesis estereoselectiva de (s)-1-metil-3-fenilpiperazina. | |
KR100846676B1 (ko) | 효소적 방법에 의한 광학활성 2-할로-2-(엔-치환된페닐)아세트산 에스테르와 2-할로-2-(엔-치환된페닐)아세트산의 제조 방법 | |
JPH10286098A (ja) | D−アミノ酸の製造方法、ならびにアミンの製造方法 | |
JP7280984B2 (ja) | (2s)-2-[(4r)-2-オキソ-4-プロピル-ピロリジン-1-イル]酪酸の調製のための酵素的プロセスおよびそのブリバラセタムへの変換 | |
KR100688770B1 (ko) | 효소적 방법에 의한 광학활성 (r)-2-아미노-1-부탄올의제조방법 | |
JP2846770B2 (ja) | 光学活性なトランス−2−アミノシクロヘキサノール誘導体を取得するための光学分割法 | |
JP3010382B2 (ja) | (r)−2−プロポキシベンゼン誘導体の製造法 | |
JP4720132B2 (ja) | 光学活性なn−保護−オクタヒドロ−1h−インドール−2−カルボン酸の製造方法 | |
JPWO2009099140A1 (ja) | 光学活性インドリン−2−カルボン酸類またはその誘導体の製造方法 | |
JP5329973B2 (ja) | リパーゼ触媒を用いるエナンチオ選択的アシル化とその後の硫酸による沈殿によって、ラセミ体の4−(1−アミノエチル)安息香酸メチルエステルから(r)−および(s)−4−(1−アンモニウムエチル)安息香酸メチルエステル硫酸塩を調製する方法 | |
KR20060060730A (ko) | 효모로부터 유래한 콜레스테롤에스터라제에 의한엔안티오퓨어 중간체의 효소적 합성 | |
DE602004005947T2 (de) | Verfahren zur Herstellung einer optisch aktiven Octahydro-1H-Indol-2-Carbonsäure | |
JP2006262710A (ja) | 光学活性なn−保護−プロパルギルグリシンの製造方法 | |
JP5092465B2 (ja) | ピペコリン酸の立体選択的なエステル化方法 | |
JP2006006134A (ja) | 光学活性なn−置換ピロリジン−3−カルボン酸の製造方法 | |
US7662610B2 (en) | Synthesis of intermediates for the preparation of pramipexol | |
Felluga et al. | Biotransformations in the synthesis of 2-pyrrolidinones and 2-pyrrolinones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780034576.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07807631 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008535383 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097005321 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12311048 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007807631 Country of ref document: EP |